Analyst Viewpoint
Increase in incidence of rheumatoid arthritis and surge in demand for over-the-counter (OTC) medications are expected to propel the rheumatoid arthritis drugs market size during the forecast period. Rise in initiatives of various health organizations to create awareness regarding rheumatoid arthritis and growth in need for early treatment are also boosting demand for rheumatoid arthritis medications.
Rise in geriatric population is likely to offer lucrative opportunities to vendors in the global rheumatoid arthritis drugs industry. Healthcare professionals are recommending the intake of over-the-counter (OTC) medications for the treatment of rheumatoid arthritis. Vendors are investing in precision medicine in rheumatoid arthritis treatment to expand their customer base. They are also tapping into new regions to increase their rheumatoid arthritis drugs market share.
Rheumatoid arthritis adversely affects the joints of the hands, wrists, knees, and ankles. It is a systemic disease as it ends up affecting the cardiac and respiratory systems. The symptoms constitute redness, warmth, and swelling of affected areas. Rheumatoid arthritis drugs are capable of enhancing mobility and prognosis. According to a study published by Rheumatology International entitled ‘The Global Prevalence of Rheumatoid Arthritis; a meta-analysis based on a systematic review’ in November 2020, the global prevalence of rheumatoid arthritis was close to 0.9%. Thus, rise in prevalence of rheumatoid arthritis is expected to spur the rheumatoid arthritis drugs market growth during the forecast period.
According to a study published in Frontiers in Immunology entitled ‘Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis’ in July 2021, nonsteroidal anti-inflammatory drugs (NSAIDs) inclusive of acetylsalicylate, ibuprofen, naproxen, and etodolac are used for alleviating pain, inflammation, and swelling. They are used as the very first line of treatment. R&D in anti-rheumatic drugs (DMARDs), corticosteroids, and biologic drugs is estimated to propel the rheumatoid arthritis drugs market value in the near future.
According to the World Health Organization (WHO), in 2019, 18 million people worldwide suffered from rheumatoid arthritis; out of which 13 million experienced it in severe form. Various health organizations, including the WHO, are taking measures to extend access to rheumatoid arthritis treatment. The WHO has made rehabilitation one of its top priorities through the Rehabilitation 2030 initiative. Such initiatives are projected to contribute to the rheumatoid arthritis drugs market progress during the forecast period.
According to the American College of Rheumatology and the Arthritis Foundation (ACR/AF), NSAIDs are amongst the effective OTC remedies to manage pain related to osteoarthritis (OA). Some of them include ibuprofen (Motrin) tablets for every type of OA, creams, and ointments that contain NSAIDs for OA of the hand and knee. The other NSAIDs approved by the American Academy of Orthopedic Surgeons (AAOS) are naproxen (Aleve), aspirin, and nabumetone (Refalen).
NSAIDs help in limiting the production of prostaglandins (responsible for causing inflammation and pain in the body). Elderly patients prefer OTC medications over surgeries to avert probable complications post-surgeries. The WHO recommends the reorientation of healthcare systems to promote healthy aging. The Integrated Care for Older People (ICOPE) approach helps in the promotion of person-centered assessment of older persons for designing long-term care interventions. Thus, increase in demand for OTC medications is fueling the rheumatoid arthritis drugs market development.
According to the latest rheumatoid arthritis drugs market forecast, Asia Pacific is expected to hold largest share from 2023 to 2031. Rise in geriatric population is fueling the market dynamics of the region. According to the Asian Development Bank, by 2050, one in four people in Asia Pacific is expected to be over 60 years old. The population of older persons (aged over 60) in the region is projected to triple between 2010 and 2050, reaching close to 1.3 billion people.
Surge in adoption of monoclonal antibodies and high prevalence of rheumatoid arthritis are propelling the rheumatoid arthritis drugs market statistics in North America. According to the CDC, more than 58 million people in the U.S. suffer from arthritis. As per the Government of Canada, as of September 2020, close to 374,000 people in Canada aged 16 and above suffered from rheumatoid arthritis. The industry in Europe is driven by increase in adoption of biosimilars. According to a survey in 2020, 92% of the EU clinicians prescribed biosimilars to close to 25% of patients suffering from rheumatoid arthritis.
Most rheumatoid arthritis drug manufacturers are investing in the R&D of new drugs to expand their product portfolio. AbbVie Inc., Johnson & Johnson Innovative Medicine, Amgen Inc., Pfizer Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company are key players operating in this market.
These companies have been profiled in the global market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 17.5 Bn |
| Market Forecast Value in 2031 | US$ 29.3 Bn |
| Growth Rate (CAGR) | 5.7% |
| Forecast Period | 2023-2031 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Scope for Customization | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 17.5 Bn in 2022
It is projected to grow at a CAGR of 5.7% from 2023 to 2031
Increase in incidence of rheumatoid arthritis and surge in demand for over-the-counter (OTC) medications
The hospital pharmacy segment held the largest share in 2022
Asia Pacific is estimated to dominate during the forecast period
AbbVie Inc., Johnson & Johnson Innovative Medicine, Amgen Inc., Pfizer Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Rheumatoid Arthritis Drugs Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, 2022-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Progression in Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2023–2031
6.3.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.3.2. Corticosteroids
6.3.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
6.3.4. Biologic Response Modifiers (Biologics)
6.4. Market Attractiveness, by Drug Type
7. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2031
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Market Attractiveness, by Distribution Channel
8. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Rheumatoid Arthritis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Type, 2022–2031
9.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
9.2.2. Corticosteroids
9.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
9.2.4. Biologic Response Modifiers (Biologics)
9.3. Market Value Forecast, by Distribution Channel, 2022–2031
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. Market Value Forecast, by Country, 2022–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Rheumatoid Arthritis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2022–2031
10.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
10.2.2. Corticosteroids
10.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
10.2.4. Biologic Response Modifiers (Biologics)
10.3. Market Value Forecast, by Distribution Channel, 2022–2031
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Market Value Forecast, by Country/Sub-region, 2022–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2022–2031
11.2.1. Polycarbonate (PC) Compound
11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.2.3. Corticosteroids
11.2.4. Disease Modifying Anti-rheumatic Drugs (DMARDs)
11.2.5. Biologic Response Modifiers (Biologics)
11.3. Market Value Forecast, by Distribution Channel, 2022–2031
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Market Value Forecast, by Country/Sub-region, 2022–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Rheumatoid Arthritis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2022–2031
12.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
12.2.2. Corticosteroids
12.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
12.2.4. Biologic Response Modifiers (Biologics)
12.3. Market Value Forecast, by Distribution Channel, 2022–2031
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4. Market Value Forecast, by Country/Sub-region, 2022–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2022–2031
13.2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
13.2.2. Corticosteroids
13.2.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
13.2.4. Biologic Response Modifiers (Biologics)
13.3. Market Value Forecast, by Distribution Channel, 2022–2031
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4. Market Value Forecast, by Country/Sub-region, 2022–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. AbbVie Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Johnson & Johnson Innovative Medicine
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Amgen Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Pfizer Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Novartis AG
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Sanofi S.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. F. Hoffmann-La Roche Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Bristol-Myers Squibb Company
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Eli Lilly and Company
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
List of Tables
Table 1: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031
Table 2: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 3: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Region, 2023–2031
Table 4: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country, 2023–2031
Table 5: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031
Table 6: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 7: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 8: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031
Table 9: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031
Table 10: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 11: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031
Table 12: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 13: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031
Table 15: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031
Table 16: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 17: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2023–2031
Table 18: Middle East & Africa Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031
List of Figures
Figure 1: Global Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 2: Global Rheumatoid Arthritis Drugs Market Value Share, by Drug Type, 2022
Figure 3: Global Rheumatoid Arthritis Drugs Market Value Share, by Distribution Channel, 2022
Figure 4: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 5: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 6: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 7: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 8: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 9: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region, 2023–2031
Figure 10: North America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 11: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 12: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 13: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 14: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 15: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 16: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 17: Europe Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 18: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 19: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 20: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 21: Europe America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 22: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 23: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 24: Asia Pacific Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 25: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 27: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 28: Asia Pacific America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 29: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 30: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 31: Latin America Rheumatoid Arthritis Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 32: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 34: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 35: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 36: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 37: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Middle East & Africa America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2023–2031
Figure 39: Middle East & Africa America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 40: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 41: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 42: Global Rheumatoid Arthritis Drugs Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Rheumatoid Arthritis Drugs Market
*86 figures and 60 tables includes